World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 19 March 2012
Main ID:  EUCTR2007-001125-97-ES
Date of registration: 03/12/2007
Prospective Registration: Yes
Primary sponsor: alberto forteza
Public title: Eficacia y Seguridad de Losartán vs Atenolol en la prevención de la dilatación progresiva de la aorta en la población de pacientes con Síndrome de Marfan (Losartan vs atenolol efficacy and security in aortic dilatation prevention in Marfan syndrome)
Scientific title: Eficacia y Seguridad de Losartán vs Atenolol en la prevención de la dilatación progresiva de la aorta en la población de pacientes con Síndrome de Marfan (Losartan vs atenolol efficacy and security in aortic dilatation prevention in Marfan syndrome)
Date of first enrolment: 20/05/2008
Target sample size:
Recruitment status: Authorised-recruitment may be ongoing or finished
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001125-97
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: yes Placebo: no Other: no  
Phase: 
Countries of recruitment
Spain
Contacts
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria:
Marfan syndrome patients between 7 and 60 years old.
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
a) Pregnancy or lactancy; b) Patients enrolled in other clinical trial; c) Previous cardiac or aortic surgery; d) Previous aortic disection ; e) Moderate or severe valvulopathy; f). Status NYHA III- IV; g) Respiratory, hepatic (ALT>3xLNS) or renal(creat < 30 ml/min) failure, or any other illness which modify the evaluation of the treatment.h) High hipersensibility, intolerance or contraindication to the treatment.


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
The aortic dilatation in Marfan syndrome with two different treatments: losartan vs atenolol
MedDRA version: 9.1 Level: LLT Classification code 10026829 Term: Marfan's syndrome
Intervention(s)

Trade Name: cozaar 50
Pharmaceutical Form: Capsule*
INN or Proposed INN: LOSARTAN POTASSIUM
CAS Number: 124750998
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-

Trade Name: blokium 50
Pharmaceutical Form: Capsule*
INN or Proposed INN: ATENOLOL
CAS Number: 29122687
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-

Trade Name: COZAAR INICIO 12,5 mg comprimidos recubiertos con pelicula
Pharmaceutical Form: Capsule*
INN or Proposed INN: LOSARTAN POTASSIUM
CAS Number: 124750998
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-

Trade Name: BLOKIUM 50 mg comprimidos
Pharmaceutical Form: Capsule*
INN or Proposed INN: ATENOLOL
CAS Number: 29122687
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-

Primary Outcome(s)
Main Objective: evaluate the role of losartan vs atenolol in the prevention of aortic dilatation in patients with marfan syndrome
Primary end point(s): Main variable assessed is the progression of aortic dilatation and one of the secondary variables is elasticity changes in the aorta wall in patients treated by losartan vs atenolol during 3 years of follow-up. Aorta dilatation was choosen as the main variable since it is related to dissection and aortic rupture.
Secondary Objective: Variations in elastic properties of the aortic wall.
Incidence of clinical aspects: aortic disection, aortic rupture, aortic operation or death.
Validation of the dose and efficacy of losartan.
Modificacion of dural ectasia
Secondary Outcome(s)
Secondary ID(s)
LO-AT-MARFAN
Source(s) of Monetary Support
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history